151 results on '"Svedsater, Henrik"'
Search Results
2. Correction to: Cost-consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma
3. Persistence and Adherence to ICS/LABA Drugs in UK Patients with Asthma: A Retrospective New-User Cohort Study
4. Use of Both Qualitative and Quantitative Methods to Estimate Meaningful Change Thresholds for Key Endpoints in Pediatric Asthma Trials
5. Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study
6. Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database
7. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial
8. Evaluation and quantification of treatment preferences for patients with asthma or COPD using discrete choice experiment surveys
9. Correction to: Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences
10. Relationship between the Asthma Control Test (ACT) and other outcomes: a targeted literature review
11. On the validity of contingent valuation : a psychological perspective
12. Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences
13. A descriptive follow-up interview study assessing patient-centred outcomes: Salford Lung Study in Asthma (SLS Asthma)
14. Can medicines development improve outcomes in asthma and chronic obstructive pulmonary disease management by driving effectiveness?
15. Follow-up interviews from The Salford Lung Study (COPD) and analyses per treatment and exacerbations
16. Within-trial economic analysis of resource use from COMET-ICE: A phase 3 clinical trial evaluating sotrovimab for the treatment of patients with COVID-19 at high risk of progression
17. Life Impact and Treatment Preferences of Individuals with Asthma and Chronic Obstructive Pulmonary Disease: Results from Qualitative Interviews and Focus Groups
18. Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD): follow-up interviews on patient-centred outcomes
19. Modelling the effect of beliefs about asthma medication and treatment intrusiveness on adherence and preference for once-daily vs. twice-daily medication
20. Covariation Neglect among Novice Investors
21. Psychometric properties of the Asthma Control Test in 2 randomized clinical trials
22. Encouraging Cooperation: Revisiting Solidarity and Commitment Effects in Prisoner's Dilemma Games
23. Money illusion in intuitive financial judgments: influences of nominal representation of share prices
24. Determinants of the use of heuristic choice rules in the Swedish Premium Pension Scheme: An Internet-based survey
25. A structured review evaluating content validity of the Asthma Control Test, and its consistency with U.S. guidelines and patient expectations for asthma control
26. A structured review evaluating content validity of the Asthma Control Test, and its consistency with U.S. guidelines and patient expectations for asthma control.
27. Impact of socioeconomic status on participation and outcomes in the Salford Lung Studies
28. Correction to: Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma
29. Piece of cake? Allocating rewards to third parties when fairness is costly
30. Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma
31. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study
32. COST-EFFECTIVENESS OF FLUTICASONE FUROATE PLUS VILANTEROL ON ASTHMA CONTROL IN CLINICAL PRACTICE
33. Healthcare resource utilisation (HRU) in the Asthma Salford Lung Study (SLS asthma)
34. Follow-up interviews to assess patient-centred outcomes in the Salford Lung Study in Asthma (SLS Asthma)
35. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial
36. Additional file 2: of Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthmaâ mixed treatment comparisons of clinical efficacy
37. Additional file 1: of Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthmaâ mixed treatment comparisons of clinical efficacy
38. Late Breaking Abstract - Effectiveness of Fluticasone furoate/vilanterol (FF/VI) compared to usual care (UC) in patients with asthma: The Salford Lung Study (SLS)
39. Erratum: A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices
40. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices
41. Economic valuation of the environment: how citizens make sense of contingent valuation questions
42. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study.
43. Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice
44. Adherence to asthma medication and preferences for once-daily treatment: Importance of treatment intrusiveness and patient beliefs
45. Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy
46. Modelling the effect of beliefs about asthma medication and treatment intrusiveness on adherence and preference for oncedaily vs. twice-daily medication.
47. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy
48. Ambivalent statements in contingent valuation studies: inclusive response formats and giving respondents time to think
49. Measurement properties of an asthma symptom and rescue medication use diary
50. Ease of use of the ELLIPTA dry powder inhaler: data from three randomised controlled trials in patients with asthma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.